Novo Nordisk is a Danish pharmaceutical company that researches, manufactures, and distributes medications through two main business divisions: one focused on obesity, diabetes, cardiovascular conditions, and emerging therapies, and another specializing in rare blood disorders, rare hormonal conditions, and hormone replacement treatments. The company produces insulin delivery devices, glucose monitoring applications, growth hormone pens, and an oral weight-management medication, while also collaborating with technology and biotech partners to develop new drugs and advance artificial intelligence applications in medicine. Its operations span Europe, Asia, North America, Latin America, and Africa.

entry readiness 50 · MODERATE · exit proximity 0

Value area 40.94–50.29 · 75% of 120d volume overhead · heavy supply